567 Eli Lilly and Company $LLY Shares Acquired by MRA Advisory Group

MRA Advisory Group increased its stake in Eli Lilly and Company (NYSE:LLY) by 194.2% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 859 shares of the company’s stock after acquiring an additional 567 shares during the quarter. MRA Advisory Group’s holdings in Eli Lilly and Company were worth $994,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of LLY. Lake Hills Wealth Management LLC acquired a new stake in Eli Lilly and Company during the 3rd quarter worth about $1,058,000. Worth Asset Management LLC boosted its holdings in shares of Eli Lilly and Company by 9.4% in the third quarter. Worth Asset Management LLC now owns 1,786 shares of the company’s stock worth $2,067,000 after buying an additional 153 shares during the period. Matrix Trust Co increased its position in shares of Eli Lilly and Company by 10.4% in the third quarter. Matrix Trust Co now owns 2,931 shares of the company’s stock worth $3,391,000 after acquiring an additional 275 shares in the last quarter. Crumly & Associates Inc. raised its holdings in shares of Eli Lilly and Company by 11.2% during the third quarter. Crumly & Associates Inc. now owns 882 shares of the company’s stock valued at $1,021,000 after acquiring an additional 89 shares during the period. Finally, Weaver Consulting Group lifted its position in shares of Eli Lilly and Company by 32.1% in the 3rd quarter. Weaver Consulting Group now owns 728 shares of the company’s stock valued at $842,000 after acquiring an additional 177 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts remain optimistic about Lilly’s obesity franchise. Articles highlight potential growth from Zepbound and Mounjaro, as well as next-generation candidate retatrutide, which has produced greater average weight loss in trials and could be filed with the FDA in early 2027. Oral GLP-1 candidate Foundayo also reportedly delivered better weight loss and blood-sugar control than oral semaglutide in a company analysis, supporting expectations for a broader, more convenient market. Eli Lilly: Buy The GLP-1 Growth Premium
• Positive Sentiment: Investors are also pricing in growth outside obesity. Lilly’s oncology, immunology and neuroscience businesses are expanding, while an FDA orphan-drug designation for experimental cancer treatment olomorasib may provide development incentives and future exclusivity. The company also completed early-stage trials for a basal-insulin candidate and advanced its drug-discovery collaboration with Gate Bioscience, potentially worth more than $870 million. Eli Lilly Scores FDA Win for Pancreatic Cancer Drug
• Neutral Sentiment: Several market commentaries describe positive momentum heading into third-quarter earnings and argue that Lilly’s growth outlook justifies a premium multiple. Recent performance has outpaced the broader market, and one valuation analysis sees additional upside from pipeline growth. These are largely opinion-based catalysts rather than new financial guidance. Eli Lilly: Quiet Momentum Builds Into Q3 Earnings
• Negative Sentiment: The main concern is valuation: LLY trades at roughly 40 times trailing earnings, leaving limited room for disappointing results. Commentary also warns that falling U.S. prices for Zepbound and Mounjaro could pressure margins and that investor expectations have become excessive. New WHO childhood-obesity guidelines emphasize lifestyle and public-health measures, potentially limiting near-term expectations for pharmaceutical treatment in younger patients. WHO Childhood Obesity Guidelines

Insider Activity

In related news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the transaction, the executive vice president directly owned 11,875 shares in the company, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. This trade represents a 10.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock valued at $15,958,170 over the last 90 days. 0.14% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Citigroup raised their price objective on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. The Goldman Sachs Group raised their target price on Eli Lilly and Company from $1,367.00 to $1,371.00 and gave the stock a “buy” rating in a research report on Thursday, September 17th. UBS Group set a $1,376.00 price target on Eli Lilly and Company in a report on Friday, August 7th. BMO Capital Markets reissued an “outperform” rating on shares of Eli Lilly and Company in a research report on Thursday, October 1st. Finally, Sanford C. Bernstein increased their price objective on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 14th. One research analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,312.36.

Eli Lilly and Company Stock Up 3.5%

Shares of NYSE LLY traded up $40.26 during mid-day trading on Wednesday, reaching $1,197.74. 1,234,705 shares of the company traded hands, compared to its average volume of 2,968,515. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The stock has a market cap of $1.13 trillion, a PE ratio of 40.18, a price-to-earnings-growth ratio of 1.40 and a beta of 0.46. The company’s fifty day moving average is $1,173.98 and its two-hundred day moving average is $1,092.69. Eli Lilly and Company has a fifty-two week low of $783.85 and a fifty-two week high of $1,292.65.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. The business had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The firm’s revenue was up 47.7% compared to the same quarter last year. During the same period last year, the business earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, analysts expect that Eli Lilly and Company will post 36.66 earnings per share for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.